Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Heart. 2016 Nov 15;103(11):818–826. doi: 10.1136/heartjnl-2016-309266

Table 2.

Prevalence of Warfarin Prescription, Stratified by Severity of Kidney Disease

eGFR Group
≥120
(N=278)
105–119
(N=2018)
90–104
(N=13257)
60–89
(N=62174)
45–59
(N=26939)
30–44
(N=13411)
15–29
(N=3787)
<15
(N=679)
Dialysis
(N=645)
Total
(N=123188)
Warfarin receipt at 90 days 57.2% 60.4% 61.6% 56.7% 55.0% 52.5% 52.1% 46.4% 62.3% 56.3%

Any warfarin during follow-up 61.5% 68.4% 70.2% 64.6% 62.6% 59.7% 58.4% 52.9% 69.9% 64.0%

Unadjusted OR of warfarin receipt at 90 days 0.83 (0.65–1.06) 0.95 (0.86–1.04) (reference group) 0.82 (0.79–0.85) 0.76 (0.73–0.80) 0.69 (0.66–0.72) 0.68 (.63–0.73) 0.54 (0.46–0.63) 1.03 (0.88–1.21)

Adjusted OR of warfarin receipt at 90 days
Full Cohort 0.53(0.40–0.71) 0.80 (0.71–0.90) (reference group) 1.11 (1.06–1.16) 1.15 (1.09–1.21) 1.06 (1.00–1.12) 1.14 (1.04–1.25) 0.78 (0.66–0.93) 1.08 (0.90–1.29)
CHADS2 ≥ 1 0.58(0.41–0.83) 0.85 (0.73–0.98) (reference group) 1.11 (1.05–1.17) 1.15 (1.09–1.23) 1.07 (1.00–1.12) 1.14 (1.03–1.25) 0.79 (0.66–0.95) 1.04 (0.87–1.25)
CHADS2 = 0 0.49(0.30–0.80) 0.77 (0.63–0.94) (reference group) 1.08 (0.995–1.18) 1.07 (0.96–1.21) 0.94 (0.78–1.13) 1.09 (0.77–1.56) 0.58 (0.32–1.06) 1.69 (0.49–5.78)
Age ≥ 75 0.76 (0.41–1.39) (reference group) 1.07 (0.94–1.23) 1.07 (0.94–1.23) 0.98 (0.86–1.12) 1.12 (0.95–1.31) 0.82 (0.63–1.06) 1.28 (0.92–1.77)
Age < 75 0.66(0.50–0.88) 0.91 (0.81–1.02) (reference group) 1.01 (0.96–1.06) 1.02 (0.96–1.08) 0.95 (0.87–1.04) 1.02 (0.88–1.19) 0.70 (0.55–0.90) 0.96 (0.77–1.20)
Heart Failure 0.97(0.43–2.19) 0.83 (0.59–1.15) (reference group) 1.14 (0.995–1.31) 1.16 (1.01–1.34) 1.11 (0.96–1.29) 1.24 (1.02–1.51) 0.79 (0.57–1.10) 1.03 (0.77–1.38)
No Heart Failure 0.48(0.35–0.66) 0.80 (0.71–0.91) (reference group) 1.10 (1.05–1.16) 1.14 (1.08–1.21) 1.05 (0.99–1.12) 1.13 (1.02–1.26) 0.79 (0.65–0.97) 1.15 (0.91–1.45)

OR = odds ratio